With an estimated one in ten humans globally suffering from one or more autoimmune conditions, it is no surprise that drugs such as adalimumab (Humira) and ustekinumab (Stelara) are some of the best-selling pharmaceuticals in the world. These drugs work by causing a systemic reduction in immune activity, which reduces the body’s attacks on itself but simultaneously thwarts its ability to fight infections. Immunosuppression is a major drawback to these therapies, says Jeffrey Hubbell, a tissue and molecular engineer at the University of Chicago.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscription info for Chinese customers

We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

doi: https://doi.org/10.1038/d41591-024-00024-2

The Clinical Pipeline is a column on translational and clinical research, from bench to bedside.

Jobs